Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

FDA Plans to Require REMS for Opioid Painkillers

  • Post author:Sam
  • Post published:January 19, 2017
  • Post category:International Pharmaceutical Regulatory Monitor

The FDA plans to require risk evaluation and mitigation strategies for opioid analgesics — including immediate, extended-release and long-acting formulations — to ensure the benefits outweigh the risks of misuse,…

Continue ReadingFDA Plans to Require REMS for Opioid Painkillers

AEMPS Suspends Spanish Manufacturer’s License

  • Post author:Sam
  • Post published:January 19, 2017
  • Post category:International Pharmaceutical Regulatory Monitor

Spain’s Agency of Medicines and Medical Devices has ordered Madrid vaccine maker Angulema to suspend manufacturing and recall drug batches over GMP deficiencies. Source: International Pharmaceutical Regulatory Monitor

Continue ReadingAEMPS Suspends Spanish Manufacturer’s License

DOJ Recovers $1.2 Billion in False Claims From Life Science Industry

  • Post author:Sam
  • Post published:January 19, 2017
  • Post category:International Pharmaceutical Regulatory Monitor

The Justice Department recovered $4.7 billion in False Claims Act settlements, with the largest recoveries coming from the life sciences industry at $1.2 billion in the last fiscal year. Source:…

Continue ReadingDOJ Recovers $1.2 Billion in False Claims From Life Science Industry

Japan to Share GMP Inspection Findings on API Makers

  • Post author:Sam
  • Post published:January 19, 2017
  • Post category:International Pharmaceutical Regulatory Monitor

Japan’s Pharmaceutical and Medical Devices Agency is joining the ranks of the FDA, the EMA and a few other drug regulators by agreeing to participate in a program that allows…

Continue ReadingJapan to Share GMP Inspection Findings on API Makers

Indian Authorities Report 27 Drugs Failed Quality Tests

  • Post author:Sam
  • Post published:December 13, 2016
  • Post category:International Pharmaceutical Regulatory Monitor

Indian drug regulators in seven states have accused 18 drugmakers of selling substandard therapies after quality tests identified a range of product issues ranging from deceptive labeling to inappropriate quantities…

Continue ReadingIndian Authorities Report 27 Drugs Failed Quality Tests

EMA: Less Data Required for Expanding Orphan Drug Indications

  • Post author:Sam
  • Post published:December 13, 2016
  • Post category:International Pharmaceutical Regulatory Monitor

The European Medicines Agency published new guidance on whether less comprehensive data can be used to support a new indication for a previously approved orphan drug product. Source: International Pharmaceutical…

Continue ReadingEMA: Less Data Required for Expanding Orphan Drug Indications

Drugmakers Criticize German Proposal to Set Drug Price Ceiling

  • Post author:Sam
  • Post published:December 13, 2016
  • Post category:International Pharmaceutical Regulatory Monitor

Drugmakers have expressed concern about the German government’s proposal to restrict drug pricing — contending that the measure penalizes research and development. Source: International Pharmaceutical Regulatory Monitor

Continue ReadingDrugmakers Criticize German Proposal to Set Drug Price Ceiling

EMA: Comparative Studies Not Required for Heparin Biosimilar

  • Post author:Sam
  • Post published:December 13, 2016
  • Post category:International Pharmaceutical Regulatory Monitor

The development process for biosimilar heparins no longer requires a comparative clinical trial, according to new guidance from the European Medicines Agency. Source: International Pharmaceutical Regulatory Monitor

Continue ReadingEMA: Comparative Studies Not Required for Heparin Biosimilar

EMA Finalizes Guideline on Active Chemical Substances

  • Post author:Sam
  • Post published:December 13, 2016
  • Post category:International Pharmaceutical Regulatory Monitor

The European Medicines Agency adopted a final guideline setting out the information required for the evaluation of active chemical substances used in drug products. Source: International Pharmaceutical Regulatory Monitor

Continue ReadingEMA Finalizes Guideline on Active Chemical Substances

ICH Adopts Update to GCP Guideline; Regional Guidances to Follow

  • Post author:Sam
  • Post published:December 13, 2016
  • Post category:International Pharmaceutical Regulatory Monitor

The International Council for Harmonisation adopted an update to its good clinical practice guideline, recommending approaches to clinical trial design and management, as well as ensuring patient protection and data…

Continue ReadingICH Adopts Update to GCP Guideline; Regional Guidances to Follow
  • Go to the previous page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.